Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets
Hikma had said in January that it was planning to buy those assets
Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.
Hikma, which supplies generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, had said in January it was planning to buy those assets.
(Edits by EP News Bureau)